VASICAN

PRODUCT DESCRIPTION:

1) Tablet : Green, round and flat tablets, with 8 mm diameter, score-line on

one side and 'DHA' logo on the other side.

2) 4mg/5mlsyrup : Clear light green syrup, sweet taste with banana flavour.

COMPOSITION:

Each Vasican tablet contains: Bromhexine HCI BP 8mg/tablet

Excipients:

Corn Starch, Lactose Mesh, Acacia Powder, FDC Blue No.1 Aluminum Lake HT, Quinoline Yellow E104, Magnesium Staerate.

Each 5ml:

Vasican 4mg/5ml syrup contains: Bromhexine HCI BP 4mg/5ml

Preservative : Benzoic Acid 0.1%w/v

Excipients : Granulated Fine White Sugar, Glycerin, Propylene Glycol, Alcohol

96%, Banana Flavor, Quinoline Yellow E104, Edicol Brilliant Blue FCF, Citric Acid Monohydrate, Sodium Citrate Dihydrate, Di-Sodium

EDTA, Purified Water.

PHARMACOLOGY:

VASICAN contains bromhexine HCI which is a mucolyticagent. It acts on the mucous gland in the respiratory tract to change the structure of bronchial secretion and to increase the volume and reduce the viscosity of the sputum.

PHARMACOKINETICS:

Oral administration Bromhexine HCl is absorbed rapidly from the gastro-intestinal tract, with peak plasma concentration achieved in about one hour. It undergoes extensive findpass metabolism in the liver and has an elimination half-life of 6.5 hours.

INDICATIONS:

For the reduction of sputum viscosity.

RECOMMENDED DOSAGE:

Tablets:

Adult and children over 12 years : 8mg (1 tablet) 3 times a day Children: 6 to 12 years : 4 mg (half tablet) 3 times a day

Syrup

Adults and children over 12 years : 8 mg (10ml) 3 times a day
Children: 6 to 12 years : 4 mg (5ml) 3 times a day
2 to 6 years : 4 mg (5ml) 2 times a day

WARNINGS AND PRECAUTIONS:

Bromhexine HCI should be given with caution to patient with gastric ulceration. In very few cases, severe skin disorders such as Stevens-Johnson's syndrome and toxic epidermal necrolysis (TEN) have been reported after administration of mucolytic substances (e.g.bromhexine), which in most cases could be explained by the patients underlying disease and/or the concomitant medication. In addition during the early phase of a Steven-Johnson Syndrome or TEN a patient may find experience non-specific influenza-like prodromes (e.g. fever, aching body, rhinitis, cough and sore throat). It is possible that a symptomatic treatment is started with a cough and cold preparation due to these misleading nonspecific influenza-like prodromes. Therefore if new skin or mucosal lesions occur, medical advice should be sought immediately and treatment with bromhexine discontinued as a precaution.

USE IN PREGNANCY AND LACTATION:

It is advisable to avoid use during the first three months of pregnancy and during lactation, Bromhexine HCI is excreted in breast milk.

DRUG INTERACTION:

Bromhexine HCI enhance the penetration of antibiotic (e.g. amoxycillin, cefuroxime, erythromycin and doxycycline) into the lung tissues. In elderly patients with acute exacerbation of chronic bronchopulmonary disease, a combination of cephalexin and bromhexine HCI shows that the symptoms and ventilatory functions were improved to a greater extent in the group treated with antibiotic and mucolytic combination than with the antibiotic alone. No other clinically unfavourable interaction with medication have been reported.

CONTRA-INDICATIONS:

Known hypersensitivity to bromhexine.

SIDE EFFECTS:

Gastro-intestinal irritations, allergic reactions including skin rashes, bronchospasm, angio-oedema and anaphylaxis, transient increased serum amino transaminase.

OVERDOSAGE AND TREATMENT:

To date, no symptoms of overdosage have been reported.

STORAGE:

Protect from light

Store below 30°C.

EXPIRY PERIOD:

Do not use after the expiry date stated on the label.

AVAILABILITY

Tablets : 10x10x10's in blister pack

Syrup : Bromhexine HCl 4mg/5ml: 100 ml in amber glass bottle and 3.8 Litres in

plastic container

DATE OF REVISION: May 2021

For further Information, please consult your physician or pharmacist.

Manufactured By: PT Actavis Indonesia JI. Raya Bogor Km 28 Jakarta Timur 13710 Indonesia

